Posts

Posted on

Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China

Significant Reduction in Triglyceride
Levels
Without
Low-Density Lipoprotein Cholesterol
(
LDL-C
)
Increase
Compared to Placebo
and Safety Profile Similar to Placebo
Achieved with 4 Grams Per Day Dose of
Icosapent
Ethyl
in Chinese Patients with Very High Triglycerides
(

>

500 mg/dL)

Results
Support
Upcoming
Submi
s
sion
by Partner
,
Edding
, Seeking
Regulatory
Approval
in China

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today shared positive, statistically significant top-line results from Protocol Number EDPC003R01, a Phase 3 clinical trial of VASCEPA® (icosapent ethyl) conducted in China by Amarin partner, Edding. The study, which investigated VASCEPA as a treatment for patients with very high triglycerides (≥500 mg/dL), met its primary efficacy endpoint as defined in the clinical trial protocol and demonstrated a safety profile similar to placebo. The findings are being prepared to support Edding’s dossier for seeking regulatory approval of VASCEPA in Mainland China.

The EDPC003R01 trial was a multi-center, randomized, double-blind, placebo-controlled, 12-week pivotal study in adult patients in China with qualifying fasting triglyceride (TG) levels greater than or equal to 500 mg/dL and less than or equal to 2000 mg/dL. The median baseline TG levels in the study were 812 mg/dL and 837 mg/dL for the patients assigned to placebo (n=123) and 4 grams per day of VASCEPA (n=122), respectively. Prior to randomization into the 12-week double-blind treatment period, all patients underwent a six- to eight-week washout period of lipid altering drugs, as well as diet and lifestyle stabilization.

The study’s primary endpoint, the percent change in TG levels from baseline to week 12, was met for the 4 gram per day VASCEPA dose group. The patient group assigned to 4 grams per day of VASCEPA showed a statistically significant median TG decrease of 19.9% (p<0.001) compared to placebo at the end of the 12-week treatment period.

Consistent with Amarin’s MARINE study in a similar patient population, the 4 gram per day dose of VASCEPA in the EDPC003R01 trial did not result in a significant median increase from baseline in low-density lipoprotein cholesterol (LDL-C) compared to placebo at the end of the 12-week treatment period. The primary results of MARINE were published in the American Journal of Cardiology1 in June 2011. Results from the MARINE study were the basis for VASCEPA’s initial approval in the United States for triglyceride lowering before the successful results of the REDUCE-IT® cardiovascular outcomes study.

Importantly, the VASCEPA 4 gram per day dose in EDPC003R01 appeared to be well-tolerated with a safety profile similar to placebo. There were no treatment-related serious adverse events in the EDPC003R01 study.

“We are proud to share news of these positive data from our partner’s pivotal Phase 3 clinical study of VASCEPA in China. Elevated triglycerides are a known marker of risk for pancreatitis and for cardiovascular disease. The statistically significant reduction in TG levels seen with the VASCEPA 4 gram per day dose in the study highlights its potential to address an unmet medical need in China, where hypertriglyceridemia is on the rise,” said Steven Ketchum, Ph.D., senior vice president and president, research & development and chief scientific officer at Amarin. “This pivotal study in China mirrored Amarin’s MARINE study in patients from the United States and other countries, and we are pleased that the data show consistency across the Chinese and non-Chinese study populations. With these favorable data, we now look forward to supporting our partner, Edding, in compiling and submitting its dossier at the earliest possible opportunity for regulatory review in China.”

“We are very pleased that the Phase III clinical study of VASCEPA in Mainland China has achieved positive results. Cardiovascular (CV) disease is the largest cause of death in China with significant unmet needs to address. Prevention and treatment of CV diseases is one of the major initiatives promoted by Health China 2030. VASCEPA is anticipated to be launched to further address these pressing needs. We will try our best to promote VASCEPA to market as soon as possible in order to benefit more Chinese patients,” said Mr. Xin Ni, founder, chairman and CEO of Edding. “VASCEPA has huge commercial potential in the fast-growing Chinese market. We will work with Amarin to submit the new drug application as soon as possible to bring this cross-era innovative drug to China.”

Amarin intends to support Edding in its pursuit of an appropriate label for VASCEPA in China reflecting the results of EDPC003R01 and all other available data supporting the safety and efficacy of VASCEPA.

About
Edding
Edding is a leading integrated pharmaceutical company in China. Edding’s vision is to become a leading ‘Global for China’ pharmaceutical company focusing on three core therapeutic areas, namely anti-infectives, cardiovascular disease and respiratory system, by leveraging Edding’s market-tested full value chain capabilities. For more information about Edding, visit www.eddingpharm.com.

About
Hypertriglyceridemia
in China

There were approximately 180.4 million hypertriglyceridemia (HTG) patients in China in 2019, representing approximately 20.2% of the adult population. Among all HTG patients in China, there were approximately 9 million adults who had very high TG levels (≥500 mg/dL). In 2019, there were approximately 36.1 million statin-treated adult patients in China with elevated TG levels (≥150 mg/dL) and either established CVD or diabetes mellitus and two or more additional risk factors for CVD, the addressable patients of the FDA-approved indication for reducing CV events of VASCEPA in China.

About Amarin

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. VASCEPA is not yet approved and available in any other countries. Amarin, on its own or together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, Europe and the Middle East. For more information about Amarin, visit www.amarincorp.com.

About
VASCEPA

®

(
icosapent
ethyl) Capsules

VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million times. VASCEPA is covered by most major medical insurance plans. The new, cardiovascular risk indication for VASCEPA was approved by the FDA in December 2019.

Indications and Limitation of Use

VASCEPA is indicated:

  • As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
    • established cardiovascular disease or
    • diabetes mellitus and two or more additional risk factors for cardiovascular disease.
  • As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information

  • VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
  • VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.
  • It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
  • VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.
  • Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).
  • Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).
  • Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
  • Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.

Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below:

Effect of
VASCEPA
on Time to First Occurrence of Cardiovascular Events in Patients with

Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT

  VASCEPA Placebo VASCEPA

vs Placebo
N = 4089

n (%) 		Incidence Rate

(per 100
patient years) 		N = 4090

n (%) 		Incidence Rate

(per 100
patient years) 		Hazard Ratio
(95% CI)
Primary composite endpoint
Cardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina (5-point MACE) 705
(17.2)		 4.3 901
(22.0)		 5.7 0.75
(0.68, 0.83)
Key secondary composite endpoint
Cardiovascular death, myocardial infarction, stroke (3-point MACE) 459
(11.2)		 2.7 606
(14.8)		 3.7 0.74
(0.65, 0.83)
Other secondary endpoints
Fatal or non-fatal myocardial infarction 250
(6.1)		 1.5 355
(8.7)		 2.1 0.69
(0.58, 0.81)
Emergent or urgent coronary revascularization 216
(5.3)		 1.3 321
(7.8)		 1.9 0.65
(0.55, 0.78)
Cardiovascular death [1] 174
(4.3)		 1.0 213
(5.2)		 1.2 0.80
(0.66, 0.98)
Hospitalization for unstable angina [2] 108
(2.6)		 0.6 157
(3.8)		 0.9 0.68
(0.53, 0.87)
Fatal or non-fatal stroke 98
(2.4)		 0.6 134
(3.3)		 0.8 0.72
(0.55, 0.93)
[1] Includes adjudicated cardiovascular deaths and deaths of undetermined causality.
[2] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization.

FULL
VASCEPA

PRESCRIBING INFORMATION

CAN BE FOUND AT

WWW.


VASCEPA


.COM

.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the potential impact of VASCEPA in clinical use and expectations for regulatory filings and approval submissions. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development, clinical trials and regulatory reviews. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Investor Inquiries:

Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
[email protected] (investor inquiries)

Solebury Trout
[email protected]

Media Inquiries:

Alina Kolomeyer
Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
[email protected] (media inquiries)

________________________
1 Bays HE, Ballantyne CM, Kastelein JJ et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients with Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol. 2011;108:682-690.



Posted on

Frontier Communications Prices $1.55 Billion First Lien Secured Notes Offering and $1.00 Billion Second Lien Secured Notes Offering

Frontier Communications Prices $1.55 Billion First Lien Secured Notes Offering and $1.00 Billion Second Lien Secured Notes Offering

NORWALK, Conn.–(BUSINESS WIRE)–
Frontier Communications Corporation (OTC: FTRCQ) (“Frontier Communications”) announced today that it has priced its previously announced offering of $1.55 billion aggregate principal amount of First Lien Secured Notes due 2028 (the “First Lien Secured Notes”) and $1.00 billion aggregate principal amount of Second Lien Secured Notes due 2029 (the “Second Lien Secured Notes” and, together with the First Lien Secured Notes, the “Notes”) in a private transaction. The First Lien Secured Notes will bear interest at 5.00% per year and will be sold at a price equal to 100% of the principal thereof. The Second Lien Secured Notes will bear interest at 6.75% per year and will be sold at a price equal to 100% of the principal thereof. The settlement of the Notes is expected to occur on or about November 25, 2020, subject to customary closing conditions.

Frontier Communications intends to use the proceeds from the offering, together with proceeds of the new $750 million incremental first lien term loan facility and cash on hand to (i) repay all outstanding borrowings under our prepetition term loan B-1 facility due 2024, (ii) repay in full the existing prepetition 8.500% Second Lien Secured Notes due 2026, and (iii) pay related interest, fees and expenses incurred in connection therewith. The offering of Notes is subject to market and other conditions.

As previously disclosed, on April 14, 2020, Frontier Communications and certain of its subsidiaries commenced voluntary cases (the “Chapter 11 Cases”) under Chapter 11 of the United States Bankruptcy Code (“Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”). On August 27, 2020, the Bankruptcy Court confirmed Frontier Communications’ plan of reorganization (the “Plan”) for the resolution of the outstanding claims against and interests in Frontier Communications pursuant to section 1121(a) of the Bankruptcy Code. The implementation of the Plan is dependent upon a number of conditions typical in similar reorganizations, including the obtainment of regulatory approval. On September 17, 2020, the Bankruptcy Court issued a final order authorizing Frontier Communications to obtain debtor-in-possession financing, including approval for this offering.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities mentioned in this press release in any jurisdiction in which such offer, solicitation or sale would be unlawful.

All offers of the Notes were made only by means of a private offering memorandum to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside of the United States under Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Frontier Communications

Frontier Communications Corporation (OTC: FTRCQ) offers a variety of services to residential and business customers over its fiber-optic and copper networks in 25 states, including video, high-speed internet, advanced voice, and Frontier Secure® digital protection solutions. Frontier Business™ offers communications solutions to small, medium, and enterprise businesses.

Forward-Looking Statements

This press release contains “forward-looking statements” related to future events. Forward-looking statements address Frontier Communications’ expected future business, financial performance, and financial condition, and contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “may,” “will,” “would,” or “target.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For Frontier Communications, particular uncertainties that could cause actual results to be materially different than those expressed in such forward-looking statements include: our ability to continue as a going concern; our ability to successfully consummate the restructuring of our existing debt, existing equity interests, and certain other obligations (the “Restructuring”), and emerge from the Chapter 11 Cases in Bankruptcy Court, including by satisfying both the conditions in the Plan and the conditions and milestones in the restructuring support agreement; our ability to improve our liquidity and long-term capital structure and to address our debt service obligations through the Restructuring and the potential adverse effects of the Chapter 11 Cases on our liquidity and results of operations; our ability to maintain relationships with suppliers, customers, employees and other third parties as a result of the Restructuring and the Chapter 11 Cases; the effects of the Restructuring and the Chapter 11 Cases on us and the interests of various constituents; risks and uncertainties associated with the Restructuring, including our ability to satisfy the conditions precedent for effectiveness of and successfully consummate the Restructuring in accordance with the Plan under the Chapter 11 Cases; our ability to comply with the restrictions expected to be imposed by covenants in debtor-in-possession and exit financing; the length of time that we will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of the Chapter 11 Cases; risks associated with third party motions in the Chapter 11 Cases, which may interfere with the Company’s ability to consummate the Restructuring; increased administrative and legal costs related to the Chapter 11 process; declines in revenue from our voice services, switched and nonswitched access and video and data services that we cannot stabilize or offset with increases in revenue from other products and services; declines in Adjusted EBITDA relative to historical levels that we are unable to offset through potential EBITDA enhancements; our ability to successfully implement strategic initiatives, including opportunities to enhance revenue and realize productivity improvements; our ability to effectively manage our operations, operating expenses, capital expenditures, debt service requirement and cash paid for income taxes and liquidity; competition from cable, wireless and wireline carriers, satellite, and over the top companies, and the risk that we will not respond on a timely or profitable basis; our ability to successfully adjust to changes in the communications industry, including the effects of technological changes and competition on our capital expenditures, products and service offerings; risks related to disruption in our networks, infrastructure and information technology that result in customer loss and/or incurrence of additional expenses; the impact of potential information technology or data security breaches or other cyber-attacks or other disruptions; our ability to retain or attract new customers and to maintain relationships with customers, employees or suppliers; our ability to secure, continue to use or renew intellectual property and other licenses used in our business; changes to our board of directors and management team upon our emergence from bankruptcy or in anticipation of emergence, and our ability to hire or retain key personnel; our ability to dispose of certain assets or asset groups on terms that are attractive to us, or at all; the effects of changes in the availability of federal and state universal service funding or other subsidies to us and our competitors and our ability to obtain future federal and state universal service funding and other subsidies; our ability to meet our Connect America Fund (“CAF”) Phase II obligations and the risk of penalties or obligations to return certain CAF Phase II funds; our ability to defend against litigation and potentially unfavorable results from current pending and future litigation; our ability to comply with applicable federal and state consumer protection requirements; the effects of state regulatory requirements that could limit our ability to transfer cash among our subsidiaries or dividend funds up to the parent company; the effects of governmental legislation and regulation on our business, including costs, disruptions, possible limitations on operating flexibility and changes to the competitive landscape resulting from such legislation or regulation; the impact of regulatory, investigative and legal proceedings and legal compliance risks; government infrastructure projects (such as highway construction) that impact our capital expenditures; continued reductions in switched access revenues as a result of regulation, competition or technology substitutions; our ability to effectively manage service quality in the states in which we operate and meet mandated service quality metrics; the effects of changes in income tax rates, tax laws, regulations or rulings, or federal or state tax assessments, including the risk that such changes may benefit our competitors more than us, as well as potential future decreases in the value of our deferred tax assets; the effects of changes in accounting policies or practices, including potential future impairment charges with respect to our intangible assets or additional losses on assets held for sale; the effects of increased medical expenses and pension and postemployment expenses; our ability to successfully renegotiate union contracts; changes in pension plan assumptions, interest rates, discount rates, regulatory rules and/or the value of our pension plan assets, which could require us to make increased contributions to the pension plan in 2020 and beyond; adverse changes in economic, political and market conditions in the areas that we serve, the U.S. and globally, including but not limited to, changes resulting from epidemics, pandemics and outbreaks of contagious diseases, including the coronavirus global pandemic, or other adverse public health developments; and potential adverse impacts of the COVID-19 pandemic on our business and operations, including potential disruptions to the work of our employees arising from health and safety measures such as social distancing and working remotely, our ability to effectively manage increased demand on our network, our ability to maintain relationships with our current or prospective customers and vendors as well as their abilities to perform under current or proposed arrangements with us, and stress on our supply chain. Forward-looking statements are also subject to the risk factors and cautionary language described from time to time in the reports the Company files with the U.S. Securities and Exchange Commission, including those in the Company’s most recent Annual Report on Form 10-K and any updates thereto in the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These risks and uncertainties may cause actual future results to be materially different than those expressed in such forward-looking statements. Frontier Communications has no obligation to update or revise these forward-looking statements and does not undertake to do so.

Investors:

Jacob Noyes

203-614-5074

Sr. Analyst, Treasury and Investor Relations

[email protected]

Media:

Javier Mendoza

562-305-2345

Vice President, Corporate Communications and External Affairs

[email protected]

Meaghan Repko / Jed Repko

Joele Frank Wilkinson Brimmer Katcher

212-355-4449

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Technology Networks Telecommunications

MEDIA:

Posted on

Kingswood Acquisition Corp. Prices $100 Million Initial Public Offering

Kingswood Acquisition Corp. Prices $100 Million Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
Kingswood Acquisition Corp., a newly organized blank check company formed as a Delaware corporation, today announced the pricing of its initial public offering of 10 million units at an offering price of $10.00 per unit, with each unit consisting of one share of Class A common stock and three-fourths of a warrant, with each whole warrant entitling the holder thereof to purchase one share of Class A common stock at $11.50 per share. The units will trade on the New York Stock Exchange under the ticker symbol “KWAC.U” beginning November 20, 2020. Kingswood Acquisition Corp. expects the initial public offering to close on November 24, 2020, subject to customary closing conditions. Once the securities comprising the units begin separate trading, the Class A common stock and the warrants are expected to be traded on the NYSE under the symbols “KWAC” and “KWAC WS,” respectively.

Oppenheimer & Co. Inc. is the sole bookrunning manager for the IPO and Odeon Capital Group, LLC is the lead manager. Kingswood Acquisition Corp. has granted the underwriters a 30-day option to purchase up to 1,500,000 additional units at the IPO price to cover over-allotments, if any.

A registration statement relating to the securities sold in the initial public offering has been declared effective by the U.S. Securities and Exchange Commission on November 19, 2020. The offering is being made only by means of a prospectus. When available, copies of the prospectus related to this offering may be obtained from Oppenheimer & Co. Inc. at 85 Broad St., New York, NY 10004 or by visiting EDGAR on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kingswood Acquisition Corp.

Kingswood Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company intends to identify a target business in the financial services industry with a focus on delivering differentiated financial services in the wealth management, financial advisory and investment management sectors to the mass affluent and private client investor community. Kingswood Acquisition Corp. is led by Gary Wilder, Group CEO of Kingswood (AIM: KWG) and Executive Chairman of Kingswood US, who will serve as Executive Chairman and Director, and Michael Nessim, President of Kingswood US and CEO of Benchmark Investments, who will serve as CEO and Director. Kingswood Acquisition Corp.’s Board of Directors includes Larry Roth, managing partner of RLR Strategic Partners LLC, a consulting firm to senior management teams, boards of directors and advisory boards of wealth management firms and former Chief Executive Officer of Cetera Financial Group.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the IPO and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

For media:

Abby Aylman Cohen

Greentarget

917-596-4758

[email protected]

For investors:

Gary Wilder

Executive Chairman

Kingswood Acquisition Corp.

+447770337995

[email protected]

Michael Nessim

Chief Executive Officer

Kingswood Acquisition Corp.

917-848-0971

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo
Posted on

Herbalife Nutrition Congratulates the 2020 NBA Draft Picks and Its Sponsored Athletes Heading to the Pros

Herbalife Nutrition Congratulates the 2020 NBA Draft Picks and Its Sponsored Athletes Heading to the Pros

LOS ANGELES–(BUSINESS WIRE)–
Herbalife Nutrition, a premier global nutrition company, congratulates its sponsored basketball athletes who participated in the 2020 National Basketball Association (NBA) Draft for their commitment to nutrition and peak sports performance. In preparation for the upcoming season, the athletes went through intense basketball training and conditioning at the Herbalife Nutrition IMPACT Center.

This annual program tests a player’s mental and physical readiness to play professional basketball, including the right weight and body composition. This year, two of our sponsored athletes who trained at the Herbalife Nutrition IMPACT Center were drafted last night.

“We work closely with Herbalife Nutrition IMPACT Basketball Center because we both understand that training in combination with personalized nutrition is critical for athletes to maximize their performance both on and off the court,” said Ibi Montesino, senior vice president and managing director for North America, Herbalife Nutrition.

At the end of the program, these collegiate athletes were drafted into the NBA:

  • Zeke Nnaji— former forward for the University of Arizona—was picked No. 22 overall and signed by the *Denver Nuggets.
  • Tyler Bey— former guard for the University of Colorado— was picked No. 36 overall and signed by the *Dallas Mavericks.

As the premier destination for basketball, the Herbalife Nutrition IMPACT Basketball Center is recognized for welcoming players at all levels. More than 200 players ranging from professionals, collegiate stars, and high school players and teams worldwide have trained at this facility. In addition to developing skills on the court, athletes also learn about the importance of nutrition.

“Nutrition is one of the four core principles of our player development strategy,” said Joe Abunassar, founder and president of the Herbalife Nutrition IMPACT Basketball Centers. “This partnership benefits not only our players but also the trainers at our other facilities.”

Herbalife Nutrition sponsors more than 150 sports events, teams, and athletes around the world. To learn more about Herbalife Nutrition sponsored athletes, visit IamHerbalifeNutrition.com.

To receive the latest company updates from Herbalife Nutrition, follow @HerbalifeNews.

*Herbalife Nutrition is not affiliated with, nor are its products and services endorsed by, the National Basketball Association.

About Herbalife Nutrition Ltd.

Herbalife Nutrition is a global company that has been changing people’s lives with great nutrition products and a proven business opportunity for its independent distributors since 1980. The Company offers high-quality, science-backed products, sold in over 90 countries by entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle. Through the Company’s global campaign to eradicate hunger, Herbalife Nutrition is also committed to bringing nutrition and education to communities around the world.

For more information on nutrition visit Herbalife.com.

Herbalife Nutrition

Anna Garcia

213-745-0542

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Basketball Licensing (Sports) Sports Other Retail Fitness & Nutrition Marketing Communications Specialty Health Retail

MEDIA:

Logo
Logo
Posted on

ROSEN, NATIONAL TRIAL LAWYERS, Reminds Las Vegas Sands Corp. Investors of Important December 21 Deadline in Securities Class Action – LVS

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Las Vegas Sands Corp. (NYSE: LVS) between February 27, 2016 and September 15, 2020, inclusive (the “Class Period”), of the important December 21, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Las Vegas Sands investors under the federal securities laws.

To join the Las Vegas Sands class action, go to http://www.rosenlegal.com/cases-register-1948.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Marina Bay Sands, a Las Vegas Sands resort in Singapore, casino’s control measures pertaining to fund transfers had weaknesses; (2) the Marina Bay Sands’ casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company’s anti-money laundering procedures; (3) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (4) Las Vegas Sands had inadequate disclosure controls and procedures; (5) consequently, all the foregoing issues were untimely disclosed; and (6) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 21, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1948.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



Posted on

ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm – BIIB

PR Newswire

NEW YORK, Nov. 19, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the “Class Period”) of the important January 12, 2021 lead plaintiff deadline in the securities class action commenced by the Firm. The lawsuit seeks to recover damages for Biogen investors under the federal securities laws.

To join the Biogen class action, go to http://www.rosenlegal.com/cases-register-1981.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants’ statements about Biogen’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1981.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-recognized-investor-counsel-reminds-biogen-inc-investors-of-important-january-12-deadline-in-first-filed-securities-class-action-commenced-by-the-firm-encourages-investors-with-losses-in-excess-of-1-million-to-contact-t-301177696.html

SOURCE Rosen Law Firm, P.A.

Posted on

Liberty Health Sciences Reaches Agreement to Settle Pending Class Action Lawsuit

PR Newswire

TORONTO, Nov. 19, 2020 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company“), a provider of high-quality cannabis, today announced that it has signed a memorandum of understanding regarding settlement of the securities class action that was commenced against it in the United States in 2019. The Company has agreed that $1.8 million US will be paid to settle all claims. The settlement is made without any admission or finding of liability and is subject to court approval. There is no assurance that the settlement agreement will receive court approval.

About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a high-quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale. For more information, please visit: www.libertyhealthsciences.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to whether the settlement agreement will receive court approval. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/liberty-health-sciences-reaches-agreement-to-settle-pending-class-action-lawsuit-301177729.html

SOURCE Liberty Health Sciences Inc.

Posted on

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of HDS, UROV, AKER, and TGC Mergers

WILMINGTON, Del., Nov. 19, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating:

HD Supply Holdings
, Inc. (NASDAQ GS
:

HDS

) regarding possible breaches of fiduciary duties and other violations of law related to HD Supply’s agreement to be acquired by The Home Depot, Inc. Under the terms of the agreement, HD Supply’s shareholders will receive $56.00 per share in cash. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-hd-supply-holdings-inc.

Urovant
Sciences Ltd.
(NASDAQ G
S:

UROV

) regarding possible breaches of fiduciary duties and other violations of law related to Urovant’s agreement to be acquired by Sumitovant Biopharma Ltd. Under the terms of the agreement Urovant’s shareholders will receive $16.25 per share in cash. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-urovant-sciences-ltd.

Akers Biosciences
, Inc. (NASDAQ GS
:

AKER

) regarding possible breaches of fiduciary duties and other violations of law related to Akers Biosciences’ agreement to merge with MYMD Pharmaceuticals, Inc. Under the terms of the agreement, Akers Biosciences will issue a number of shares of Akers Biosciences’ common stock to shareholders of MYMD. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-akers-biosciences-inc.

Tengasco
, Inc. (N
YSE:

TGC

) regarding possible breaches of fiduciary duties and other violations of law related to Tengasco’s agreement to merge with Riley Exploration – Permian, LLC. Under the terms of the agreement, Tengasco will issue 97.796467 shares of Tengasco common stock to each shareholder of Riley Exploration. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-tengasco-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com



Posted on

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IPHI, XLNX, ALSK, and EIGI Mergers

WILMINGTON, Del., Nov. 19, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating:

Inphi
Corporation
(N
ASDAQ GS:

IPHI

) regarding possible breaches of fiduciary duties and other violations of law related to Inphi’s agreement to be acquired by Marvell Technology Group Ltd. Under the terms of the agreement Inphi’s shareholders will receive 2.323 shares of Marvell Technology’s common stock and $66.00 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-inphi-corporation.

Xilinx, Inc
. (NASDAQ G
S:

XLNX

) regarding possible breaches of fiduciary duties and other violations of law related to Xilinx’s agreement to be acquired by Advanced Micro Devices, Inc. Under the terms of the agreement, Xilinx’s shareholders will receive 1.7234 shares of Advanced Micro Devices per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-xilinx-inc.

Alaska Communications Systems Group, Inc. (NASDAQ GS:

ALSK

) regarding possible breaches of fiduciary duties and other violations of law related to Alaska Communications’ agreement to be acquired by affiliates of GCM Grosvenor. Under the terms of the agreement, Alaska Communications’ shareholders will receive $3.00 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-alaska-communications-systems-group-inc.

Endurance International Group Holdings, Inc. (NASDAQ GS:

EIGI

) regarding possible breaches of fiduciary duties and other violations of law related to Endurance International’s agreement to be acquired by affiliates of Clearlake Capital Group L.P. Under the terms of the agreement, Endurance International’s shareholders will receive $9.50 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-endurance-international-group-holdings-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com



Posted on

ROSEN, GLOBAL INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Wells Fargo & Company; Encourages Investors with Losses in Excess of $100K to Contact Firm – WFC

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Wells Fargo & Company (NYSE: WFC) between October 13, 2017 and October 13, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Wells Fargo investors under the federal securities laws.

To join the Wells Fargo class action, go to http://www.rosenlegal.com/cases-register-1985.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Wells Fargo had systematically failed to follow appropriate underwriting standards and due diligence guidelines in issuing billions of dollars’ worth of commercial loans, including by inflating the net income and future expected cash flows of its commercial clients to justify issuing excessive loan amounts; (2) a materially higher proportion of Wells Fargo’s commercial loan customers were of poor credit quality and/or at a substantially higher risk of default than disclosed to investors; (3) Wells Fargo had failed to timely write down commercial loans, collateralized loan obligations (“CLOs”) and commercial mortgage backed securities (“CMBS”) on its books that had suffered impairments; (4) Wells Fargo had materially understated the reserves needed for expected credit losses in its commercial portfolios; (5) Wells Fargo had systematically misrepresented the credit quality and likelihood of default of the loans it packaged and securitized into CLOs and CMBS, including by artificially inflating the net income and expected cash flows of its commercial clients in loan and securitization documentation; (6) the CLO and CMBS-related loans issued and investment securities held by Wells Fargo were of lower credit quality and worth far less than represented to investors; (7) as a result of the foregoing, Wells Fargo’s Class Period statements regarding the credit quality of its commercial loans, its underwriting and due diligence practices, and the value of its CLO and CMBS books were materially false and misleading and (8) as a result of the foregoing, Wells Fargo was exposed to severe undisclosed risks of financial, reputational and legal harm, in particular in the event of significant and sustained stress in the commercial credit markets. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1985.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com